PRESS RELEASE: clinical study for our lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV), completes recruitment!

Articles » PRESS RELEASE: clinical study for our lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV), completes recruitment!

"Really fantastic feeling to have finalized enrolment of the 150 patients in our placebo-controlled study in bacterial vaginosis #Nefertiti - What an achievement by the Gedea Biotech AB team, the sites, LINK Medical Research, Link2Trials - and what a milestone for us!" 

Read the full press release on the Gedea Biotech AB website: Link

PRESS RELEASE: clinical study for our lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV), completes recruitment!

The randomized double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by Nottingham University Hospitals NHS Trust across 6 UK and 4 Swedish sites. Results from the first treatment period (day 0-7) are expected in Q2 and for the follow-up period in Q3. This would put us in a strong position to achieve #CEmarking by the end of the year.